PLX stock forecast, quote, news & analysis
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs... Show more
Protalix BioTherapeutics (PLX) Stock Analysis: Fabry Disease Franchise Momentum Meets a Modest Pullback
Key Takeaways
- Protalix BioTherapeutics (PLX) has traded in a narrow band in recent weeks, with the share price easing roughly 6% over the trailing 30 days.
- The company's core growth engine remains Elfabrio, its Fabry disease therapy commercialized globally through partner Chiesi Farmaceutici.
- Second-quarter 2026 revenue reached $19.9 million, with net income of $3.8 million, reflecting continued commercial execution and a first-quarter $25 million milestone from Chiesi.
- Management has reaffirmed full-year 2026 revenue guidance of $78 million to $83 million, including the milestone payment.
- Pipeline catalyst PRX-115, an enzyme therapy for uncontrolled gout, is advancing in a Phase 2 study, with top-line results expected in the second half of 2027.
- For deeper detail, explore the company's Price Targets, Earnings, and Forecast pages.
- For AI-driven trading ideas across the market, visit Tickeron's Trending AI Robots.
Current Market Snapshot
Protalix BioTherapeutics has maintained a relatively stable trading profile through the second half of 2026, with shares fluctuating in a range around the mid-$2 level. The modest pullback over the trailing month reflects typical small- and micro-cap biotech volatility rather than a fundamental shift in the business, as the company continues to report profitable quarters and reiterate its annual guidance.
Investor attention remains focused on the commercial trajectory of Elfabrio, the company's enzyme replacement therapy for Fabry disease, and on the progress of its clinical pipeline. With a market capitalization in the low hundreds of millions of dollars and a debt-free balance sheet, PLX occupies a distinctive niche as a rare-disease developer that is currently generating positive net income.
Protalix BioTherapeutics (PLX) Business Overview and Competitive Position
Protalix BioTherapeutics is a biopharmaceutical company focused on the discovery, development, production, and commercialization of recombinant therapeutic proteins for rare diseases. Its proprietary ProCellEx platform uses plant cell-based expression to manufacture proteins at industrial scale without exposure to mammalian cells, and the company was the first to gain FDA approval for a protein produced through this approach.
The company currently has two approved, commercially available enzyme replacement therapies. Elelyso (taliglucerase alfa), for Gaucher disease, is licensed to Pfizer worldwide except in Brazil, where Protalix retains full rights and sells through Fiocruz. Elfabrio (pegunigalsidase alfa), for Fabry disease, was approved by both the FDA and the European Medicines Agency in May 2023 and is commercialized globally through a partnership with Chiesi Farmaceutici.
Beyond its commercial portfolio, Protalix is advancing two pipeline candidates: PRX-115, a plant cell-expressed PEGylated uricase for uncontrolled gout, and PRX-119, a long-acting DNase I for NETs-related diseases. The company's rare-renal-disease focus, partnered commercialization model, and profitable operating base are key reasons investors follow the stock.
Recent Developments Driving PLX
Several verified developments have shaped investor sentiment toward Protalix in recent months. In the first quarter of 2026, the company recognized a $25 million milestone payment from Chiesi following European approval of an every-four-weeks dosing regimen for Elfabrio, a change management believes reduces treatment burden and strengthens the product's competitive positioning in the Fabry market.
Second-quarter results underscored continued commercial momentum. Total revenue rose to $19.9 million from $15.7 million a year earlier, driven by higher Elfabrio sales to Chiesi, and the company posted net income of $3.8 million. Management also noted a U.S. patent term extension for Elfabrio through November 2035 and marketing authorization in South Korea, secured in May 2026.
On the analyst front, H.C. Wainwright reiterated a Buy rating on the stock in September 2026. Looking ahead, Protalix is scheduled to report third-quarter results and present at the Stifel 2026 Healthcare Conference in November, events that could provide updated color on Elfabrio demand trends and PRX-115 enrollment progress.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated showcase of the platform's AI-driven trading bots. While Tickeron offers hundreds of automated trading bots that collectively trade thousands of tickers, only the top-performing and most relevant bots appear in this featured section, giving users a focused view of strategies that are currently standing out.
The bots in this section vary widely by strategy, timeframe, and performance metrics, ranging from short-term technical setups to longer-horizon trend approaches. This diversity lets traders compare different methodologies and evaluate how automated systems are positioning across the market. Investors looking to complement their own research with data-driven, algorithmic perspectives may find the page a useful starting point for discovering new trading ideas.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will be important for Protalix's performance through the remainder of 2026 and into 2027. The primary commercial driver remains Elfabrio, where continued global penetration through Chiesi and uptake of the expanded dosing regimen in Europe will shape revenue growth. Management has guided full-year 2026 total revenue of $78 million to $83 million and Elfabrio sales, excluding milestones, of $33 million to $35 million.
Clinical progress on PRX-115 is a key longer-term catalyst. The ongoing Phase 2 RELEASE study in uncontrolled gout is expected to deliver top-line results in the second half of 2027, and management has indicated it aims to finalize patient enrollment around year-end 2026. Investors will also monitor the advancement of PRX-119 and any additional regulatory milestones from the Chiesi collaboration.
As with any small-cap biotech, risks include quarter-to-quarter revenue variability tied to partner ordering patterns, clinical trial outcomes, and broader market conditions. Protalix's debt-free balance sheet and cash position of $40.7 million as of June 30, 2026 provide financial flexibility, but the company's outlook remains closely tied to execution across its commercial partnerships and pipeline programs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for PLX turns positive, indicating new upward trend
PLX saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 79 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PLX just turned positive on November 10, 2026. Looking at past instances where PLX's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
PLX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for PLX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 32 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (3.498). P/E Ratio (10.583) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.697) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant therapeutic proteins
Industry Biotechnology